Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial.

Vicente Navarro-López, Asunción Martínez-Andrés, Ana Ramírez-Boscá, Beatriz Ruzafa-Costas, Eva Núñez-Delegido, Miguel A Carrión-Gutiérrez, David Prieto-Merino, Francisco Codoñer-Cortés, Daniel Ramón-Vidal, Salvador Genovés-Martínez, Empar Chenoll-Cuadros, José M Pérez-Orquín, José A Picó-Monllor, Sara Chumillas-Lidón

Journal: Acta dermato-venereologica 2020;99(12):1078-1084

PMID: 31453631

Plain Language Summary

plain language summary logo

Psoriasis is as an immune-mediated, inflammatory dermatological disease characterized by a chronic-relapsing course and associated with multifactorial inheritance. The elevation of inflammatory markers is characteristic in peripheral blood of patients with psoriasis. The aim of this study was to determine the efficacy and safety of a probiotic mixture in the reduction of psoriasis severity. This study is a double-blind, randomised (1:1) placebo-controlled trial. Ninety patients were recruited, evaluated by 3 dermatologists and randomly assigned to one of the two trial arms (probiotics or control). Results show: - a beneficial effect of the probiotic blend, in reducing the severity of psoriasis when administered as coadjutant therapy together with topical corticosteroid. - the efficacy of the probiotic in modulation of the composition of the microbiota. - that patients previously treated with the probiotic mixture have a lower risk of relapse than those who previously received placebo. Authors conclude that more studies are required with the inclusion of patients younger than 18 years, the use of different doses of probiotics, different durations of probiotic administration and different strains, for comparison with the current results.

Abstract

The aim of this 12-week randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of a probiotic mixture in the reduction of psoriasis severity. Ninety 18-70-year-old adults with plaque psoriasis were randomized into probiotic and placebo groups. At 12-week follow-up, 66.7% of patients in the probiotic group and 41.9% in the placebo group showed a reduction in Psoriasis Area and Severity Index of up to 75% (p < 0.05). A clinically relevant difference was observed in Physician Global Assessment index: 48.9% in the probiotic group achieved a score of 0 or 1, compared with 30.2% in the placebo group. The results of follow-up 6 months after the end of the study showed a lower risk of relapse after the intake of the probiotic mixture. Analysis of gut microbiota confirmed the efficacy of the probiotic in modulation of the microbiota composition.

Address: Clinical Medicine, MiBioPath Group, Universidad Católica San Antonio de Murcia, ES-30107 Guadalupe, Murcia, Spain. [email protected].

Patient Centred Factor

Laboratory Testing

Modifiable Lifestyle Factors

Jadad Score

Allocation Concealment

Bioactive Substances

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.